摘要
支气管哮喘（简称哮喘）是由多种因素引起的疾病，目前公认的发病机制是气道炎症假说。近来研究表明，胰岛素受体底物（insulin receptor substrate，IRS）在哮喘发病中也起很大作用，通过探索IRS如IRS1、IRS-2和SHC（SHC是含有SH结构域的基因编码的蛋白产物），尤其是SHC在哮喘中的作用机制，将有望在哮喘治疗上提出新的治疗方向。
Bronchial asthma is a disease caused by a variety of factors, the currently accepted pathogenesis is mainly airway inflammation hypothesis. Recently, mangy reports have demonstrated that the insulin receptor substrate （IRS） also plays an important role in the pathogcnesis of bronchial asthma, by exploring IRS, such as the IRS-I.IRS-2 and SHe, especially the SHc, in the action mechanism of bronchial asthma, is expected to propose a new therapeutic direction in bronchial asthma treatment.
出处
《国际呼吸杂志》
2012年第20期1580-1582,共3页
International Journal of Respiration
基金
广西自然科学基金项目（桂科自0832146）
关键词
支气管哮喘
发病机制
胰岛素受体底物
细胞免疫
Bronchial asthma
Pathogenesis
Insulin receptor substrate
Cellular immunity
